U.S. markets closed
  • S&P 500

    4,128.80
    +31.63 (+0.77%)
     
  • Dow 30

    33,800.60
    +297.03 (+0.89%)
     
  • Nasdaq

    13,900.19
    +70.88 (+0.51%)
     
  • Russell 2000

    2,243.47
    +0.88 (+0.04%)
     
  • Crude Oil

    59.34
    -0.26 (-0.44%)
     
  • Gold

    1,744.10
    -14.10 (-0.80%)
     
  • Silver

    25.33
    -0.26 (-1.02%)
     
  • EUR/USD

    1.1905
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.6660
    +0.0340 (+2.08%)
     
  • GBP/USD

    1.3707
    -0.0028 (-0.20%)
     
  • USD/JPY

    109.6300
    +0.3660 (+0.33%)
     
  • BTC-USD

    59,673.83
    -1,266.64 (-2.08%)
     
  • CMC Crypto 200

    1,235.89
    +8.34 (+0.68%)
     
  • FTSE 100

    6,915.75
    -26.47 (-0.38%)
     
  • Nikkei 225

    29,768.06
    +59.08 (+0.20%)
     

Recap: ACADIA Pharmaceuticals Q4 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) decreased in after-market trading after the company reported Q4 results.

Quarterly Results

Earnings per share decreased 23.53% year over year to ($0.42), which beat the estimate of ($0.47).

Revenue of $121,007,000 up by 23.07% from the same period last year, which missed the estimate of $123,200,000.

Guidance

ACADIA Sees FY21 Net Sales For NUPLAZID $510M-$550M

Details Of The Call

Date: Feb 24, 2021

Time: 04:30 PM

View more earnings on ACAD

ET Webcast URL: https://edge.media-server.com/mmc/p/euu8bxfd

Price Action

52-week high: $58.72

Company's 52-week low was at $30.02

Price action over last quarter: Up 0.64%

Company Profile

Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.